After interim data failed to meet the statistical criteria for success, CureVac NV is pressing ahead to complete development of its first Covid-19 vaccine while making plans to start studies of a second generation compound later this year. On 16 June, CureVac announced that its messenger RNA vaccine, CVnCoV, demonstrated an interim efficacy rate of 47% in a Phase 2b/3 trial. The outcome was weaker than expected.
